ClinicalTrials.gg
CompletedNCT04546425Updated Jan 8, 2024Results posted

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 66 sites in 12 countries. Open to participants aged 42 Days to 112 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,258
Allocation
Randomized
Ages
42 Days to 112 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
6th of 19
1,258 · median 668
Started
2020
with 4 others
Phase 3
14 of 19
1 open now
Registered
6th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 6th largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 6th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 112 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
42 Days to 112 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female infants born at >36 weeks of gestation and 2 months of age at the time of consent.
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis).
  • Major known congenital malformation or serious chronic disorder.
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,258 participants (actual)

Study arms

  • Experimental
    20-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine

    Biological: 20-valent pneumococcal conjugate vaccine

  • Active comparator
    13-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population

    Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 1

  2. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study Population

    Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 2

  3. Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Primary Study Population

    Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 3

  4. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study Population

    Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 Days after Dose 1

  5. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study Population

    Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever: was defined as temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 Days after Dose 2

  6. Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Primary Study Population

    Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: was defined as temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) \& severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 Days after Dose 3

  7. Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: Primary Study Population

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.

    Time frame: From Dose 1 to 1 month after Dose 2

  8. Percentage of Participants With Adverse Events (AEs) From Dose 3 to 1 Month After Dose 3: Primary Study Population

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.

    Time frame: From Dose 3 to 1 month after Dose 3

  9. Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 3: Primary Study Population

    A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.

    Time frame: From Dose 1 to 1 month after Dose 3

  10. Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Dose 1 to 1 Month After Dose 3: Primary Study Population

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.

    Time frame: From Dose 1 to 1 month after Dose 3

  11. Percentage of Participants With Predefined Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 2: Primary Study Population

    Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 month after Dose 2

  12. Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 2: Primary Study Population

    Pneumococcal serotype-specific IgG concentration was measured for serum sample for 13vPnC serotype: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 7 additional serotype: 8, 10A, 11A, 12F, 15B, 22F, 33F. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, corresponding 2-sided 95% CIs (based on Student's t distribution). Assay result below LLOQ was set to 0.5\*LLOQ. Geometric mean ratios (GMRs) were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CIs (based on Student's t distribution).

    Time frame: 1 month after Dose 2

  13. GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 3: Primary Study Population

    Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 7 additional serotype: 8, 10A, 11A, 12F, 15B, 22F,33F. GMC and corresponding 2-sided 95% CI were calculated by exponentiating mean logarithm of concentrations and corresponding 2-sided 95% CI (based on Student's t distribution). Assay result below LLOQ were set to 0.5\*LLOQ. GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution).

    Time frame: 1 month after Dose 3

  14. Percentage of Participants With Predefined Antibody Levels for Concomitant Vaccine Antigens 1 Month After Dose 3: Primary Study Population

    Diphtheria and tetanus toxoids: concentration of antibody (AB) (in international units \[IU\]) to diphtheria \& tetanus toxoid (prespecified level\>=0.1 IU/mL); Pertussis antigens-pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN): prespecified level \>=observed Anti pertussis Antibody concentration achieved by 95% of 13vPnC recipient; HBsAg prespecified level \>=10 milli-IU per mL (mIU/mL); Poliovirus strains (types 1, 2 and 3): prespecified level: \>=1:8; Hemophilus influenzae type b(Hib): prespecified level \>=0.15 microgram per millilitre (mcg/mL) polyribosylribitol phosphate (anti-PRP) in mcg/mL. Concomitant vaccine response was assessed from subset of randomly selected study participants.

    Time frame: 1 month after Dose 3

  15. GMC of Measles Virus Antibody 1 Month After Dose 3: Primary Study Population

    Pre-specified vaccine antigen (measles) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.

    Time frame: 1 month after Dose 3

  16. GMC of Mumps Virus Antibody 1 Month After Dose 3: Primary Study Population

    Pre-specified vaccine antigen (mumps) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.

    Time frame: 1 month after Dose 3

  17. GMC of Rubella Virus Antibody 1 Month After Dose 3: Primary Study Population

    Pre-specified vaccine antigen (rubella) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.

    Time frame: 1 month after Dose 3

  18. GMC of Varicella Virus Antibody 1 Month After Dose 3: Primary Study Population

    Pre-specified vaccine antigen (varicella) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.

    Time frame: 1 month after Dose 3

  19. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Russian Cohort

    Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 1

  20. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Russian Cohort

    Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 2

  21. Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Russian Cohort

    Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 3

  22. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Russian Cohort

    Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using e-diary. Fever: temperature \>=38.0 degree C \& categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.

    Time frame: Within 7 Days after Dose 1

  23. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Russian Cohort

    Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.

    Time frame: Within 7 Days after Dose 2

  24. Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Russian Cohort

    Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.

    Time frame: Within 7 Days after Dose 3

  25. Percentage of Participants With AEs From Dose 1 to 1 Month After Dose 2: Russian Cohort

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.

    Time frame: From Dose 1 to 1 month after Dose 2

  26. Percentage of Participants With AEs From Dose 3 to 1 Month After Dose 3: Russian Cohort

    An AE was any untoward medical occurrence in a participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.

    Time frame: From Dose 3 to 1 month after Dose 3

  27. Percentage of Participants With SAEs From Dose 1 to 1 Month After Dose 3: Russian Cohort

    A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.

    Time frame: From Dose 1 to 1 month after Dose 3

  28. Percentage of Participants With NDCMC From Dose 1 to 1 Month After Dose 3: Russian Cohort

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.

    Time frame: From Dose 1 to 1 month after Dose 3

  29. Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 2: Russian Cohort

    Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B. \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 month after Dose 2

  30. GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 2: Russian Cohort

    Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. Assay results below the LLOQ were set to 0.5 \* LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, and the corresponding 2-sided 95% CIs (based on Student's t distribution).

    Time frame: 1 month after Dose 2

  31. GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 3: Russian Cohort

    Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and additional serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Assay results below the LLOQ were set to 0.5 \* LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, and the corresponding 2-sided 95% CIs (based on Student's t distribution).

    Time frame: 1 month after Dose 3

Secondary outcomes

  1. Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 3: Primary Study Population

    Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 Month after Dose 3

  2. Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) 1 Month After Dose 2: Primary Study Population

    OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 2. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.

    Time frame: 1 month after Dose 2

  3. Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) 1 Month After Dose 3: Primary Study Population

    OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.

    Time frame: 1 Month after Dose 3

  4. Geometric Mean Fold Rise (GMFRs) of IgG Concentrations From Before Dose 3 to 1 Month After Dose 3: Primary Study Population

    20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution).

    Time frame: Before Dose 3 to 1 month after Dose 3

  5. Percentage of Participants With Predefined Antibody Levels for Concomitant Vaccine Antigens 1 Month After Dose 2: Primary Study Population

    Pre-specified vaccines were administered concomitantly with 20vPnC or 13vPnC and responses assessed using pre-defined levels as follows: Diphtheria and tetanus toxoids: concentration of antibody (in international units \[IU\]) to diphtheria and tetanus toxoid (prespecified level \>= observed anti-pertussis antibody concentration achieved by 95% of 13vPnC recipients); Poliomyelitis: NA titers to poliovirus types 1, 2, and 3 (prespecified level NA titer \>=1:8); and Hib: concentration of antibody to Hib (PRP) in mcg/mL (prespecified level \>=0.15 mcg/mL anti-PRP). 2-sided 95% CI was based on Clopper and Pearson method. The assays were performed on randomly selected subsets.

    Time frame: 1 month after Dose 2

  6. Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 3: Russian Cohort

    Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 Month after Dose 3

  7. GMTs of Serotype-specific OPA at 1 Month After Dose 2: Russian Cohort

    OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 2. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the student's t distribution.

    Time frame: 1 month after Dose 2

  8. GMTs of Serotype-specific OPA at 1 Month After Dose 3: Russian Cohort

    OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the student's t distribution.

    Time frame: 1 Month after Dose 3

07

Results

Posted May 15, 2023

Participant flow

Participant flow — Overall Study
Milestone20vPnC: Primary Study Population13vPnC: Primary Study Population20vPnC: Russian Cohort13vPnC: Russian Cohort
Started6016032427
Dose 16016032427
Dose 25935982427
Dose 35885942225
Completed5835902225
Not completed181322
Withdrew: Protocol violation1100
Withdrew: Adverse event3000
Withdrew: Lost to follow-up5400
Withdrew: No longer met eligibility criteria3311
Withdrew: Withdrawal by parent/guardian6511

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population

Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Redness: Mild20.7 ± 17.622.7 ± 19.4
Redness: Moderate4.5 ± 3.04.8 ± 3.2
Redness: Severe0 ± 0.00 ± 0.0
Swelling: Mild12.7 ± 10.112.9 ± 10.4
Swelling: Moderate8.7 ± 6.67.3 ± 5.4
Swelling: Severe0 ± 0.00 ± 0.0
Pain at Injection Site: Mild16.7 ± 13.817.9 ± 14.9
Pain at Injection Site: Moderate12.0 ± 9.511.4 ± 9.0
Pain at Injection Site: Severe0.3 ± 0.00 ± 0.0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study Population

Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Redness: Mild24.8 ± 21.422.9 ± 19.6
Redness: Moderate3.7 ± 2.35.1 ± 3.4
Redness: Severe0 ± 0.00.2 ± 0.0
Swelling: Mild13.7 ± 11.014.1 ± 11.4
Swelling: Moderate8.3 ± 6.26.2 ± 4.4
Swelling: Severe0 ± 0.00.2 ± 0.0
Pain at Injection Site: Mild13.3 ± 10.716.5 ± 13.6
Pain at Injection Site: Moderate9.3 ± 7.17.9 ± 5.9
Pain at Injection Site: Severe0.2 ± 0.00.2 ± 0.0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 3: Primary Study Population

Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Redness: Mild23.3 ± 19.925.1 ± 21.6
Redness: Moderate13.4 ± 10.88.5 ± 6.4
Redness: Severe0.2 ± 0.00.2 ± 0.0
Swelling: Mild17.8 ± 14.714.5 ± 11.8
Swelling: Moderate11.9 ± 9.49.7 ± 7.5
Swelling: Severe0.2 ± 0.00.3 ± 0.0
Pain at Injection Site: Mild24.7 ± 21.222.4 ± 19.0
Pain at Injection Site: Moderate17.4 ± 14.417.2 ± 14.3
Pain at Injection Site: Severe0.3 ± 0.00.3 ± 0.0
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study Population

Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Fever: >=38.0 degrees C to 38.4 degrees C7.5 ± 5.56.8 ± 4.9
Fever: >38.4 degrees C to 38.9 degrees C1.3 ± 0.61.3 ± 0.6
Fever: >38.9 degrees C to 40.0 degrees C0 ± 0.00.3 ± 0.0
Fever: >40.0 degrees C0 ± 0.00 ± 0.0
Decreased appetite: Mild16.2 ± 13.413.3 ± 10.7
Decreased appetite: Moderate7.5 ± 5.58.8 ± 6.7
Decreased appetite: Severe1.0 ± 0.40.5 ± 0.1
Drowsiness: Mild46.0 ± 41.948.6 ± 44.5
Drowsiness: Moderate14.4 ± 11.714.3 ± 11.6
Drowsiness: Severe0.8 ± 0.30.8 ± 0.3
Irritability: Mild17.6 ± 14.617.4 ± 14.5
Irritability: Moderate46.2 ± 42.146.4 ± 42.4
Irritability: Severe8.2 ± 6.18.6 ± 6.5
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study Population

Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever: was defined as temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 Days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Fever: >=38.0 degrees C to 38.4 degrees C11.7 ± 9.211.6 ± 9.2
Fever: >38.4 degrees C to 38.9 degrees C2.5 ± 1.42.0 ± 1.0
Fever: >38.9 degrees C to 40.0 degrees C0.7 ± 0.20.3 ± 0.0
Fever: >40.0 degrees C0 ± 0.00 ± 0.0
Decreased appetite: Mild13.5 ± 10.912.1 ± 9.6
Decreased appetite: Moderate10.1 ± 7.86.4 ± 4.6
Decreased appetite: Severe1.0 ± 0.40.8 ± 0.3
Drowsiness: Mild37.8 ± 33.937.0 ± 33.1
Drowsiness: Moderate13.2 ± 10.613.5 ± 10.8
Drowsiness: Severe0.3 ± 0.00.2 ± 0.0
Irritability: Mild22.8 ± 19.521.2 ± 18.0
Irritability: Moderate43.1 ± 39.040.6 ± 36.6
Irritability: Severe5.7 ± 4.06.6 ± 4.7
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 3: Primary Study Population

Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: was defined as temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) \& severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 Days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Fever: >=38.0 degrees C to 38.4 degrees C13.4 ± 10.813.5 ± 10.8
Fever: >38.4 degrees C to 38.9 degrees C6.9 ± 5.07.0 ± 5.1
Fever: >38.9 degrees C to 40.0 degrees C3.6 ± 2.33.2 ± 2.0
Fever: >40.0 degrees C0.3 ± 0.00 ± 0.0
Decreased appetite: Mild20.0 ± 16.815.5 ± 12.7
Decreased appetite: Moderate17.1 ± 14.118.9 ± 15.8
Decreased appetite: Severe2.2 ± 1.22.0 ± 1.1
Drowsiness: Mild34.8 ± 30.932.8 ± 29.0
Drowsiness: Moderate15.3 ± 12.514.7 ± 11.9
Drowsiness: Severe0.7 ± 0.21.2 ± 0.5
Irritability: Mild23.4 ± 20.121.3 ± 18.1
Irritability: Moderate43.4 ± 39.445.4 ± 41.3
Irritability: Severe4.1 ± 2.74.1 ± 2.6
PrimaryPercentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: Primary Study Population

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.

Time frame:
From Dose 1 to 1 month after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: Primary Study Population13.8 ± 11.214.4 ± 11.7
PrimaryPercentage of Participants With Adverse Events (AEs) From Dose 3 to 1 Month After Dose 3: Primary Study Population

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.

Time frame:
From Dose 3 to 1 month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Dose 3 to 1 Month After Dose 3: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Percentage of Participants With Adverse Events (AEs) From Dose 3 to 1 Month After Dose 3: Primary Study Population15.5 ± 12.616.5 ± 13.6
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 3: Primary Study Population

A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.

Time frame:
From Dose 1 to 1 month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 3: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 3: Primary Study Population5.7 ± 3.96.6 ± 4.8
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Dose 1 to 1 Month After Dose 3: Primary Study Population

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.

Time frame:
From Dose 1 to 1 month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Dose 1 to 1 Month After Dose 3: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Dose 1 to 1 Month After Dose 3: Primary Study Population1.0 ± 0.41.0 ± 0.4
PrimaryPercentage of Participants With Predefined Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 2: Primary Study Population

Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

Time frame:
1 month after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 2: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Serotype 170.7 (66.7 to 74.4)84.2 (80.9 to 87.1)
Serotype 358.0 (53.8 to 62.1)75.8 (72.0 to 79.3)
Serotype 468.6 (64.5 to 72.4)79.5 (76.0 to 82.8)
Serotype 563.4 (59.3 to 67.4)76.0 (72.2 to 79.5)
Serotype 6A59.5 (55.4 to 63.6)73.7 (69.8 to 77.3)
Serotype 6B20.7 (17.5 to 24.3)36.5 (32.5 to 40.7)
Serotype 7F87.6 (84.6 to 90.2)90.2 (87.5 to 92.5)
Serotype 9V60.2 (56.1 to 64.3)74.6 (70.7 to 78.1)
Serotype 1478.6 (75.0 to 81.9)81.9 (78.4 to 85.0)
Serotype 18C71.0 (67.1 to 74.7)76.5 (72.8 to 80.0)
Serotype 19A92.2 (89.7 to 94.3)94.0 (91.6 to 95.8)
Serotype 19F94.3 (92.1 to 96.1)95.7 (93.7 to 97.2)
Serotype 23F23.5 (20.1 to 27.2)41.8 (37.7 to 46.0)
Serotype 896.5 (94.6 to 97.8)2.9 (1.6 to 4.6)
Serotype 10A28.9 (25.2 to 32.8)2.7 (1.5 to 4.4)
Serotype 11A94.2 (91.9 to 96.0)2.0 (1.0 to 3.5)
Serotype 12F30.3 (26.6 to 34.3)0.2 (0.0 to 1.0)
Serotype 15B94.3 (92.1 to 96.1)8.5 (6.4 to 11.2)
Serotype 22F94.4 (92.1 to 96.1)2.0 (1.0 to 3.5)
Serotype 33F46.8 (42.6 to 51.0)2.7 (1.5 to 4.4)
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference :: -13.5 · 95% CI -18.3 to -8.72-Sided 95% CIs were calculated using the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -17.9 · 95% CI -23.2 to -12.42-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -11.0 · 95% CI -16.0 to -5.92-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -12.6 · 95% CI -17.8 to -7.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -14.1 · 95% CI -19.5 to -8.62-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -15.8 · 95% CI -21.0 to -10.62-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -2.6 · 95% CI -6.3 to 1.12-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -14.3 · 95% CI -19.7 to -8.92-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -3.3 · 95% CI -7.9 to 1.42-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -5.5 · 95% CI -10.6 to -0.42-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -1.7 · 95% CI -4.8 to 1.32-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -1.4 · 95% CI -4.0 to 1.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -18.3 · 95% CI -23.6 to -12.92-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 59.9 · 95% CI 55.6 to 64.12-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -7.6 · 95% CI -13.1 to -2.12-Sided 95% CI based on the Percent difference for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 57.6 · 95% CI 53.1 to 61.92-Sided 95% CI based on the Percent difference for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -6.2 · 95% CI -11.7 to -0.72-Sided 95% CI based on the Percent difference for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 57.8 · 95% CI 53.3 to 62.12-Sided 95% CI based on the Percent difference for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 57.8 · 95% CI 53.3 to 62.12-Sided 95% CI based on the Percent difference for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 10.3 · 95% CI 4.5 to 16.02-Sided 95% CI based on the Percent difference for the difference in proportions expressed as a percentage.
PrimaryGeometric Mean Concentration (GMC) of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 2: Primary Study Population

Pneumococcal serotype-specific IgG concentration was measured for serum sample for 13vPnC serotype: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 7 additional serotype: 8, 10A, 11A, 12F, 15B, 22F, 33F. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, corresponding 2-sided 95% CIs (based on Student's t distribution). Assay result below LLOQ was set to 0.5\*LLOQ. Geometric mean ratios (GMRs) were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CIs (based on Student's t distribution).

Time frame:
1 month after Dose 2
Reported as:
Geometric mean · Microgram per millilitre (mcg/mL)
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 2: Primary Study Population
Microgram per millilitre (mcg/mL)20vPnC: Primary Study Population13vPnC: Primary Study Population
Serotype 10.57 (0.52 to 0.62)0.93 (0.86 to 1.01)
Serotype 30.41 (0.38 to 0.45)0.58 (0.54 to 0.63)
Serotype 40.55 (0.50 to 0.61)0.92 (0.83 to 1.02)
Serotype 50.34 (0.30 to 0.38)0.56 (0.50 to 0.62)
Serotype 6A0.45 (0.40 to 0.52)0.84 (0.73 to 0.95)
Serotype 6B0.03 (0.03 to 0.04)0.06 (0.05 to 0.07)
Serotype 7F1.02 (0.94 to 1.10)1.41 (1.30 to 1.53)
Serotype 9V0.45 (0.40 to 0.51)0.77 (0.68 to 0.87)
Serotype 141.05 (0.94 to 1.18)1.28 (1.14 to 1.43)
Serotype 18C0.69 (0.62 to 0.77)0.87 (0.78 to 0.98)
Serotype 19A0.67 (0.61 to 0.74)1.13 (1.01 to 1.26)
Serotype 19F2.21 (2.04 to 2.40)3.06 (2.80 to 3.34)
Serotype 23F0.13 (0.12 to 0.15)0.25 (0.22 to 0.28)
Serotype 81.62 (1.51 to 1.74)0.02 (0.02 to 0.02)
Serotype 10A0.16 (0.14 to 0.18)0.02 (0.02 to 0.02)
Serotype 11A1.62 (1.50 to 1.75)0.02 (0.02 to 0.02)
Serotype 12F0.15 (0.13 to 0.17)0.01 (0.01 to 0.01)
Serotype 15B3.33 (3.00 to 3.70)0.04 (0.04 to 0.04)
Serotype 22F2.25 (2.06 to 2.45)0.01 (0.01 to 0.01)
Serotype 33F0.31 (0.28 to 0.34)0.03 (0.02 to 0.03)
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.61 · 95% CI 0.54 to 0.692-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.71 · 95% CI 0.64 to 0.792-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.60 · 95% CI 0.52 to 0.692-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.60 · 95% CI 0.52 to 0.702-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.54 · 95% CI 0.45 to 0.652-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.51 · 95% CI 0.43 to 0.612-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.72 · 95% CI 0.64 to 0.802-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.59 · 95% CI 0.50 to 0.692-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.82 · 95% CI 0.70 to 0.962-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.79 · 95% CI 0.67 to 0.922-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.59 · 95% CI 0.51 to 0.692-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.72 · 95% CI 0.64 to 0.822-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.52 · 95% CI 0.44 to 0.622-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 26.55 · 95% CI 22.98 to 30.672-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 2.67 · 95% CI 2.25 to 3.172-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 26.60 · 95% CI 22.95 to 30.822-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 2.48 · 95% CI 2.08 to 2.972-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 54.60 · 95% CI 46.35 to 64.302-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 36.80 · 95% CI 31.57 to 42.892-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 5.03 · 95% CI 4.27 to 5.922-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
PrimaryGMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 3: Primary Study Population

Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 7 additional serotype: 8, 10A, 11A, 12F, 15B, 22F,33F. GMC and corresponding 2-sided 95% CI were calculated by exponentiating mean logarithm of concentrations and corresponding 2-sided 95% CI (based on Student's t distribution). Assay result below LLOQ were set to 0.5\*LLOQ. GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution).

Time frame:
1 month after Dose 3
Reported as:
Geometric mean · Microgram per millilitre (mcg/mL)
GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 3: Primary Study Population
Microgram per millilitre (mcg/mL)20vPnC: Primary Study Population13vPnC: Primary Study Population
Serotype 11.71 (1.58 to 1.84)2.53 (2.33 to 2.75)
Serotype 30.72 (0.67 to 0.78)1.09 (1.01 to 1.17)
Serotype 44.11 (3.77 to 4.48)5.36 (4.91 to 5.85)
Serotype 51.74 (1.60 to 1.89)2.41 (2.21 to 2.64)
Serotype 6A7.75 (7.04 to 8.53)11.82 (10.66 to 13.11)
Serotype 6B2.64 (2.36 to 2.95)4.63 (4.09 to 5.25)
Serotype 7F3.61 (3.40 to 3.84)4.93 (4.63 to 5.24)
Serotype 9V3.68 (3.42 to 3.97)5.04 (4.67 to 5.43)
Serotype 144.52 (4.08 to 5.00)5.66 (5.12 to 6.26)
Serotype 18C2.71 (2.52 to 2.93)3.61 (3.33 to 3.91)
Serotype 19A4.51 (4.11 to 4.94)5.49 (5.02 to 6.01)
Serotype 19F6.19 (5.68 to 6.75)8.08 (7.40 to 8.83)
Serotype 23F2.64 (2.40 to 2.91)4.40 (3.95 to 4.90)
Serotype 83.57 (3.32 to 3.83)0.03 (0.03 to 0.03)
Serotype 10A4.86 (4.41 to 5.36)0.01 (0.01 to 0.01)
Serotype 11A3.74 (3.44 to 4.07)0.02 (0.01 to 0.02)
Serotype 12F1.86 (1.71 to 2.01)0.01 (0.01 to 0.01)
Serotype 15B13.09 (12.10 to 14.15)0.02 (0.02 to 0.03)
Serotype 22F9.27 (8.52 to 10.08)0.00 (0.00 to 0.00)
Serotype 33F6.37 (5.83 to 6.95)0.01 (0.01 to 0.01)
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.67 · 95% CI 0.60 to 0.752-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.66 · 95% CI 0.59 to 0.732-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.77 · 95% CI 0.68 to 0.872-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.72 · 95% CI 0.64 to 0.812-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.66 · 95% CI 0.57 to 0.752-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.57 · 95% CI 0.48 to 0.672-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.73 · 95% CI 0.67 to 0.802-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.73 · 95% CI 0.66 to 0.812-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.80 · 95% CI 0.69 to 0.922-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.75 · 95% CI 0.67 to 0.842-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.82 · 95% CI 0.72 to 0.932-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.77 · 95% CI 0.68 to 0.872-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.60 · 95% CI 0.52 to 0.692-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 1.48 · 95% CI 1.32 to 1.662-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 2.02 · 95% CI 1.77 to 2.302-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 1.55 · 95% CI 1.37 to 1.752-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.77 · 95% CI 0.68 to 0.872-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 5.42 · 95% CI 4.82 to 6.102-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 3.84 · 95% CI 3.40 to 4.342-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 2.64 · 95% CI 2.33 to 2.992-sided 95% CI was calculated by exponentiating the CI (based on the Student's t distribution) for the mean difference of the logarithm of the concentrations.
PrimaryPercentage of Participants With Predefined Antibody Levels for Concomitant Vaccine Antigens 1 Month After Dose 3: Primary Study Population

Diphtheria and tetanus toxoids: concentration of antibody (AB) (in international units \[IU\]) to diphtheria \& tetanus toxoid (prespecified level\>=0.1 IU/mL); Pertussis antigens-pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN): prespecified level \>=observed Anti pertussis Antibody concentration achieved by 95% of 13vPnC recipient; HBsAg prespecified level \>=10 milli-IU per mL (mIU/mL); Poliovirus strains (types 1, 2 and 3): prespecified level: \>=1:8; Hemophilus influenzae type b(Hib): prespecified level \>=0.15 microgram per millilitre (mcg/mL) polyribosylribitol phosphate (anti-PRP) in mcg/mL. Concomitant vaccine response was assessed from subset of randomly selected study participants.

Time frame:
1 month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Antibody Levels for Concomitant Vaccine Antigens 1 Month After Dose 3: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Diphtheria toxoid99.6 (98.5 to 100.0)99.8 (98.9 to 100.0)
Tetanus toxoid99.4 (98.2 to 99.9)100.0 (99.3 to 100.0)
Pertussis: PT92.9 (90.3 to 95.0)95.2 (92.9 to 96.9)
Pertussis: FHA95.3 (93.1 to 97.0)95.2 (92.9 to 96.9)
Pertussis: PRN96.8 (94.8 to 98.1)95.2 (92.9 to 96.9)
Hepatitis B100.0 (97.9 to 100.0)98.9 (96.0 to 99.9)
Poliovirus: Type 1100.0 (95.5 to 100.0)100.0 (95.9 to 100.0)
Poliovirus: Type 2100.0 (95.5 to 100.0)100.0 (95.9 to 100.0)
Poliovirus: Type 3100.0 (95.5 to 100.0)100.0 (95.9 to 100.0)
Hemophilus influenzae type b100.0 (98.0 to 100.0)100.0 (97.8 to 100.0)
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -0.2 · 95% CI -1.3 to 0.82-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnc - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -0.6 · 95% CI -1.8 to 0.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnc - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -2.3 · 95% CI -5.3 to 0.72-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.2 · 95% CI -2.6 to 2.92-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 1.6 · 95% CI -0.9 to 4.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 1.1 · 95% CI -1.1 to 4.02-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnc - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.0 · 95% CI -4.6 to 4.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnc - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.0 · 95% CI -4.6 to 4.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnc - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.0 · 95% CI -4.6 to 4.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnc - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.0 · 95% CI -2.0 to 2.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnc - 13vPnC) expressed as a percentage.
PrimaryGMC of Measles Virus Antibody 1 Month After Dose 3: Primary Study Population

Pre-specified vaccine antigen (measles) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.

Time frame:
1 month after Dose 3
Reported as:
Geometric mean · Arbitrary units per millilitre
GMC of Measles Virus Antibody 1 Month After Dose 3: Primary Study Population
Arbitrary units per millilitre20vPnC: Primary Study Population13vPnC: Primary Study Population
GMC of Measles Virus Antibody 1 Month After Dose 3: Primary Study Population228.63 ± 186.34216.72 ± 174.92
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 1.05 · 95% CI 0.79 to 1.42GMR and 2-sided 95% CIs were calculated by exponentiating the mean differences of the logarithms of the concentrations (20vPnC - 13vPnC) and the corresponding CIs (based on the Student's t distribution).
PrimaryGMC of Mumps Virus Antibody 1 Month After Dose 3: Primary Study Population

Pre-specified vaccine antigen (mumps) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.

Time frame:
1 month after Dose 3
Reported as:
Geometric mean · Arbitrary units per millilitre
GMC of Mumps Virus Antibody 1 Month After Dose 3: Primary Study Population
Arbitrary units per millilitre20vPnC: Primary Study Population13vPnC: Primary Study Population
GMC of Mumps Virus Antibody 1 Month After Dose 3: Primary Study Population36.81 ± 29.1235.25 ± 28.14
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 1.04 · 95% CI 0.76 to 1.44GMR and 2-sided 95% CIs were calculated by exponentiating the mean differences of the logarithms of the concentrations (20vPnC - 13vPnC) and the corresponding CIs (based on the Student's t distribution).
PrimaryGMC of Rubella Virus Antibody 1 Month After Dose 3: Primary Study Population

Pre-specified vaccine antigen (rubella) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.

Time frame:
1 month after Dose 3
Reported as:
Geometric mean · International units per millilitre
GMC of Rubella Virus Antibody 1 Month After Dose 3: Primary Study Population
International units per millilitre20vPnC: Primary Study Population13vPnC: Primary Study Population
GMC of Rubella Virus Antibody 1 Month After Dose 3: Primary Study Population31.81 ± 25.5438.20 ± 32.10
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 0.83 · 95% CI 0.63 to 1.10GMR and 2-sided 95% CIs were calculated by exponentiating the mean differences of the logarithms of the concentrations (20vPnC - 13vPnC) and the corresponding CIs (based on the Student's t distribution).
PrimaryGMC of Varicella Virus Antibody 1 Month After Dose 3: Primary Study Population

Pre-specified vaccine antigen (varicella) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.

Time frame:
1 month after Dose 3
Reported as:
Geometric mean · Milli-international units per millilitre
GMC of Varicella Virus Antibody 1 Month After Dose 3: Primary Study Population
Milli-international units per millilitre20vPnC: Primary Study Population13vPnC: Primary Study Population
GMC of Varicella Virus Antibody 1 Month After Dose 3: Primary Study Population195.58 ± 165.14157.60 ± 133.57
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Geometric mean ratio: 1.24 · 95% CI 0.98 to 1.57GMR and 2-sided 95% CIs were calculated by exponentiating the mean differences of the logarithms of the concentrations (20vPnC - 13vPnC) and the corresponding CIs (based on the Student's t distribution).
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1: Russian Cohort

Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Redness: Mild4.2 ± 0.17.4 ± 0.9
Redness: Moderate4.2 ± 0.13.7 ± 0.1
Redness: Severe0 ± 0.00 ± 0.0
Swelling: Mild0 ± 0.00 ± 0.0
Swelling: Moderate4.2 ± 0.10 ± 0.0
Swelling: Severe0 ± 0.00 ± 0.0
Pain at Injection Site: Mild8.3 ± 1.07.4 ± 0.9
Pain at Injection Site: Moderate0 ± 0.03.7 ± 0.1
Pain at Injection Site: Severe0 ± 0.00 ± 0.0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2: Russian Cohort

Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Redness: Mild0 ± 0.03.7 ± 0.1
Redness: Moderate4.3 ± 0.10 ± 0.0
Redness: Severe0 ± 0.00 ± 0.0
Swelling: Mild0 ± 0.07.4 ± 0.9
Swelling: Moderate8.7 ± 1.10 ± 0.0
Swelling: Severe0 ± 0.00 ± 0.0
Pain at Injection Site: Mild8.7 ± 1.17.4 ± 0.9
Pain at Injection Site: Moderate4.3 ± 0.10 ± 0.0
Pain at Injection Site: Severe0 ± 0.00 ± 0.0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 3: Russian Cohort

Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Redness: Mild0 (0.0 to 15.4)4.0 (0.1 to 20.4)
Redness: Moderate4.5 (0.1 to 22.8)0 (0.0 to 13.7)
Redness: Severe0 (0.0 to 15.4)4.0 (0.1 to 20.4)
Swelling: Mild0 (0.0 to 15.4)0 (0.0 to 13.7)
Swelling: Moderate9.1 (1.1 to 29.2)0 (0.0 to 13.7)
Swelling: Severe0 (0.0 to 15.4)4.0 (0.1 to 20.4)
Pain at Injection Site: Mild13.6 (2.9 to 34.9)8.0 (1.0 to 26.0)
Pain at Injection Site: Moderate0 (0.0 to 15.4)0 (0.0 to 13.7)
Pain at Injection Site: Severe0 (0.0 to 15.4)0 (0.0 to 13.7)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1: Russian Cohort

Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using e-diary. Fever: temperature \>=38.0 degree C \& categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Fever: >=38.0 degrees C to 38.4 degrees C4.2 ± 0.10 ± 0.0
Fever: >38.4 degrees C to 38.9 degrees C0 ± 0.00 ± 0.0
Fever: >38.9 degrees C to 40.0 degrees C0 ± 0.00 ± 0.0
Fever: >40.0 degrees C0 ± 0.00 ± 0.0
Decreased appetite: Mild16.7 ± 4.714.8 ± 4.2
Decreased appetite: Moderate0 ± 0.03.7 ± 0.1
Decreased appetite: Severe0 ± 0.00 ± 0.0
Drowsiness: Mild20.8 ± 7.118.5 ± 6.3
Drowsiness: Moderate8.3 ± 1.011.1 ± 2.4
Drowsiness: Severe0 ± 0.00 ± 0.0
Irritability: Mild12.5 ± 2.77.4 ± 0.9
Irritability: Moderate8.3 ± 1.014.8 ± 4.2
Irritability: Severe4.2 ± 0.10 ± 0.0
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2: Russian Cohort

Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.

Time frame:
Within 7 Days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Fever: >=38.0 degrees C to 38.4 degrees C0 ± 0.011.1 ± 2.4
Fever: >38.4 degrees C to 38.9 degrees C4.3 ± 0.10 ± 0.0
Fever: >38.9 degrees C to 40.0 degrees C0 ± 0.00 ± 0.0
Fever: >40.0 degrees C0 ± 0.00 ± 0.0
Decreased appetite: Mild4.3 ± 0.17.4 ± 0.9
Decreased appetite: Moderate4.3 ± 0.13.7 ± 0.1
Decreased appetite: Severe0 ± 0.00 ± 0.0
Drowsiness: Mild4.3 ± 0.13.7 ± 0.1
Drowsiness: Moderate0 ± 0.03.7 ± 0.1
Drowsiness: Severe0 ± 0.00 ± 0.0
Irritability: Mild13.0 ± 2.822.2 ± 8.6
Irritability: Moderate4.3 ± 0.118.5 ± 6.3
Irritability: Severe0 ± 0.03.7 ± 0.1
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 3: Russian Cohort

Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.

Time frame:
Within 7 Days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Fever: >=38.0 degrees C to 38.4 degrees C0 ± 0.00 ± 0.0
Fever: >38.4 degrees C to 38.9 degrees C0 ± 0.04.0 ± 0.1
Fever: >38.9 degrees C to 40.0 degrees C4.5 ± 0.10 ± 0.0
Fever: >40.0 degrees C0 ± 0.00 ± 0.0
Decreased appetite: Mild9.1 ± 1.18.0 ± 1.0
Decreased appetite: Moderate9.1 ± 1.10 ± 0.0
Decreased appetite: Severe0 ± 0.00 ± 0.0
Drowsiness: Mild13.6 ± 2.920.0 ± 6.8
Drowsiness: Moderate0 ± 0.04.0 ± 0.1
Drowsiness: Severe0 ± 0.00 ± 0.0
Irritability: Mild27.3 ± 10.716.0 ± 4.5
Irritability: Moderate9.1 ± 1.18.0 ± 1.0
Irritability: Severe0 ± 0.00 ± 0.0
PrimaryPercentage of Participants With AEs From Dose 1 to 1 Month After Dose 2: Russian Cohort

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.

Time frame:
From Dose 1 to 1 month after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs From Dose 1 to 1 Month After Dose 2: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Percentage of Participants With AEs From Dose 1 to 1 Month After Dose 2: Russian Cohort8.3 ± 1.03.7 ± 0.1
PrimaryPercentage of Participants With AEs From Dose 3 to 1 Month After Dose 3: Russian Cohort

An AE was any untoward medical occurrence in a participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.

Time frame:
From Dose 3 to 1 month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs From Dose 3 to 1 Month After Dose 3: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Percentage of Participants With AEs From Dose 3 to 1 Month After Dose 3: Russian Cohort4.5 ± 0.10 ± 0.0
PrimaryPercentage of Participants With SAEs From Dose 1 to 1 Month After Dose 3: Russian Cohort

A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.

Time frame:
From Dose 1 to 1 month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs From Dose 1 to 1 Month After Dose 3: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Percentage of Participants With SAEs From Dose 1 to 1 Month After Dose 3: Russian Cohort0 (0 to 14.2)0 (0 to 12.8)
PrimaryPercentage of Participants With NDCMC From Dose 1 to 1 Month After Dose 3: Russian Cohort

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.

Time frame:
From Dose 1 to 1 month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With NDCMC From Dose 1 to 1 Month After Dose 3: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Percentage of Participants With NDCMC From Dose 1 to 1 Month After Dose 3: Russian Cohort0 (0 to 14.2)0 (0 to 12.8)
PrimaryPercentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 2: Russian Cohort

Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B. \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

Time frame:
1 month after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 2: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Serotype 170.8 ± 48.977.8 ± 57.7
Serotype 337.5 ± 18.859.3 ± 38.8
Serotype 475.0 ± 53.374.1 ± 53.7
Serotype 566.7 ± 44.781.5 ± 61.9
Serotype 6A54.2 ± 32.881.5 ± 61.9
Serotype 6B20.8 ± 7.159.3 ± 38.8
Serotype 7F95.8 ± 78.992.6 ± 75.7
Serotype 9V41.7 ± 22.181.5 ± 61.9
Serotype 1483.3 ± 62.685.2 ± 66.3
Serotype 18C66.7 ± 44.781.5 ± 61.9
Serotype 19A87.5 ± 67.692.6 ± 75.7
Serotype 19F79.2 ± 57.896.3 ± 81.0
Serotype 23F37.5 ± 18.870.4 ± 49.8
Serotype 875.0 ± 53.333.3 ± 16.5
Serotype 10A41.7 ± 22.118.5 ± 6.3
Serotype 11A83.3 ± 62.618.5 ± 6.3
Serotype 12F12.5 ± 2.714.8 ± 4.2
Serotype 15B66.7 ± 44.733.3 ± 16.5
Serotype 22F66.7 ± 44.714.8 ± 4.2
Serotype 33F45.8 ± 25.625.9 ± 11.1
PrimaryGMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 2: Russian Cohort

Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. Assay results below the LLOQ were set to 0.5 \* LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, and the corresponding 2-sided 95% CIs (based on Student's t distribution).

Time frame:
1 month after Dose 2
Reported as:
Geometric mean · Microgram per millilitre (mcg/mL)
GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 2: Russian Cohort
Microgram per millilitre (mcg/mL)20vPnC: Russian Cohort13vPnC: Russian Cohort
Serotype 10.76 ± 0.491.04 ± 0.64
Serotype 30.28 ± 0.190.47 ± 0.31
Serotype 40.67 ± 0.451.00 ± 0.58
Serotype 50.53 ± 0.310.75 ± 0.40
Serotype 6A0.45 ± 0.201.57 ± 0.80
Serotype 6B0.07 ± 0.030.27 ± 0.12
Serotype 7F1.06 ± 0.681.89 ± 1.32
Serotype 9V0.44 ± 0.231.22 ± 0.73
Serotype 141.56 ± 0.882.66 ± 1.46
Serotype 18C0.94 ± 0.460.94 ± 0.50
Serotype 19A1.15 ± 0.471.21 ± 0.59
Serotype 19F1.51 ± 0.843.32 ± 2.03
Serotype 23F0.25 ± 0.110.73 ± 0.37
Serotype 80.79 ± 0.370.07 ± 0.03
Serotype 10A0.31 ± 0.100.04 ± 0.01
Serotype 11A0.83 ± 0.430.04 ± 0.02
Serotype 12F0.06 ± 0.030.02 ± 0.01
Serotype 15B1.19 ± 0.460.16 ± 0.05
Serotype 22F0.48 ± 0.160.02 ± 0.01
Serotype 33F0.40 ± 0.180.07 ± 0.03
PrimaryGMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 3: Russian Cohort

Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and additional serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Assay results below the LLOQ were set to 0.5 \* LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, and the corresponding 2-sided 95% CIs (based on Student's t distribution).

Time frame:
1 month after Dose 3
Reported as:
Geometric mean · Microgram per millilitre (mcg/mL)
GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 3: Russian Cohort
Microgram per millilitre (mcg/mL)20vPnC: Russian Cohort13vPnC: Russian Cohort
Serotype 11.61 ± 0.931.65 ± 0.94
Serotype 30.84 ± 0.440.57 ± 0.32
Serotype 43.05 ± 1.503.04 ± 1.72
Serotype 51.50 ± 0.801.72 ± 0.90
Serotype 6A6.63 ± 2.965.63 ± 2.96
Serotype 6B1.94 ± 0.821.49 ± 0.67
Serotype 7F3.53 ± 1.974.14 ± 2.73
Serotype 9V2.32 ± 1.282.27 ± 1.19
Serotype 144.01 ± 1.645.06 ± 3.04
Serotype 18C2.60 ± 1.242.64 ± 1.49
Serotype 19A4.81 ± 2.072.69 ± 1.12
Serotype 19F4.97 ± 2.304.58 ± 2.36
Serotype 23F3.52 ± 1.682.96 ± 1.33
Serotype 81.33 ± 0.500.09 ± 0.04
Serotype 10A1.99 ± 0.630.03 ± 0.01
Serotype 11A1.50 ± 0.580.06 ± 0.02
Serotype 12F0.17 ± 0.050.02 ± 0.01
Serotype 15B4.90 ± 1.670.07 ± 0.03
Serotype 22F1.52 ± 0.380.02 ± 0.01
Serotype 33F1.38 ± 0.530.04 ± 0.02
SecondaryPercentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 3: Primary Study Population

Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

Time frame:
1 Month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 3: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Serotype 197.2 (95.3 to 98.4)98.2 (96.6 to 99.2)
Serotype 382.6 (79.0 to 85.8)93.2 (90.7 to 95.3)
Serotype 499.2 (97.9 to 99.8)99.2 (98.0 to 99.8)
Serotype 598.4 (96.8 to 99.3)98.0 (96.4 to 99.0)
Serotype 6A98.8 (97.4 to 99.6)98.8 (97.4 to 99.6)
Serotype 6B98.4 (96.8 to 99.3)97.6 (95.9 to 98.8)
Serotype 7F99.6 (98.5 to 100.0)100.0 (99.3 to 100.0)
Serotype 9V99.2 (97.9 to 99.8)98.8 (97.4 to 99.6)
Serotype 1496.6 (94.5 to 98.0)98.0 (96.4 to 99.0)
Serotype 18C99.2 (97.9 to 99.8)98.2 (96.6 to 99.2)
Serotype 19A99.6 (98.5 to 100.0)99.6 (98.6 to 100.0)
Serotype 19F99.6 (98.5 to 100.0)99.4 (98.3 to 99.9)
Serotype 23F96.4 (94.3 to 97.8)97.2 (95.4 to 98.5)
Serotype 899.2 (97.9 to 99.8)3.6 (2.1 to 5.6)
Serotype 10A97.8 (96.1 to 98.9)1.6 (0.7 to 3.1)
Serotype 11A98.4 (96.8 to 99.3)4.6 (2.9 to 6.8)
Serotype 12F96.6 (94.6 to 98.0)0.2 (0.0 to 1.1)
Serotype 15B99.4 (98.2 to 99.9)4.8 (3.1 to 7.0)
Serotype 22F99.2 (97.9 to 99.8)1.4 (0.6 to 2.9)
Serotype 33F98.6 (97.1 to 99.4)1.8 (0.8 to 3.4)
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -1.0 · 95% CI -3.1 to 0.92-Sided 95% CIs are calculated using the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -10.6 · 95% CI -14.7 to -6.72-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.0 · 95% CI -1.4 to 1.32-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.4 · 95% CI -1.4 to 2.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.0 · 95% CI -1.6 to 1.52-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.8 · 95% CI -1.1 to 2.72-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -0.4 · 95% CI -1.5 to 0.42-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.4 · 95% CI -1.0 to 1.92-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -1.5 · 95% CI -3.7 to 0.62-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 1.0 · 95% CI -0.5 to 2.72-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.0 · 95% CI -1.1 to 1.12-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.2 · 95% CI -0.9 to 1.42-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -0.9 · 95% CI -3.2 to 1.42-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 2.0 · 95% CI 0.4 to 3.92-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.6 · 95% CI -1.5 to 2.72-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 1.2 · 95% CI -0.7 to 3.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -0.6 · 95% CI -2.9 to 1.62-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 2.2 · 95% CI 0.7 to 4.12-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 2.0 · 95% CI 0.4 to 3.92-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 1.4 · 95% CI -0.4 to 3.42-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions expressed as a percentage.
SecondaryGeometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) 1 Month After Dose 2: Primary Study Population

OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 2. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.

Time frame:
1 month after Dose 2
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) 1 Month After Dose 2: Primary Study Population
Titers20vPnC: Primary Study Population13vPnC: Primary Study Population
Serotype 114 (12 to 16)23 (19 to 28)
Serotype 331 (26 to 36)40 (34 to 47)
Serotype 4333 (270 to 413)391 (314 to 486)
Serotype 521 (18 to 23)27 (23 to 31)
Serotype 6A347 (273 to 441)409 (318 to 527)
Serotype 6B54 (42 to 71)105 (76 to 144)
Serotype 7F858 (736 to 1000)895 (781 to 1027)
Serotype 9V233 (182 to 298)285 (228 to 358)
Serotype 14287 (215 to 383)360 (264 to 489)
Serotype 18C588 (467 to 741)719 (590 to 876)
Serotype 19A57 (43 to 75)91 (69 to 121)
Serotype 19F97 (81 to 116)117 (94 to 146)
Serotype 23F59 (42 to 84)68 (48 to 96)
Serotype 8164 (133 to 203)17 (15 to 18)
Serotype 10A855 (610 to 1199)39 (34 to 44)
Serotype 11A327 (253 to 423)49 (47 to 51)
Serotype 12F4788 (3779 to 6067)26 (23 to 28)
Serotype 15B846 (605 to 1183)17 (15 to 19)
Serotype 22F4444 (3666 to 5386)10 (9 to 11)
Serotype 33F2373 (1759 to 3202)178 (163 to 195)
SecondaryGeometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) 1 Month After Dose 3: Primary Study Population

OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.

Time frame:
1 Month after Dose 3
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) 1 Month After Dose 3: Primary Study Population
Titers20vPnC: Primary Study Population13vPnC: Primary Study Population
Serotype 154 (43 to 69)101 (79 to 129)
Serotype 399 (84 to 117)129 (111 to 150)
Serotype 4904 (752 to 1086)992 (777 to 1266)
Serotype 560 (50 to 72)82 (66 to 101)
Serotype 6A1101 (897 to 1350)1304 (1018 to 1671)
Serotype 6B537 (408 to 706)864 (664 to 1125)
Serotype 7F1811 (1553 to 2112)2197 (1905 to 2533)
Serotype 9V3254 (2596 to 4079)4544 (3681 to 5610)
Serotype 14738 (606 to 899)926 (751 to 1142)
Serotype 18C1296 (1048 to 1602)1870 (1489 to 2348)
Serotype 19A754 (627 to 907)707 (558 to 896)
Serotype 19F183 (140 to 237)258 (192 to 347)
Serotype 23F697 (530 to 917)975 (734 to 1296)
Serotype 81398 (1088 to 1796)31 (25 to 39)
Serotype 10A3403 (2600 to 4455)69 (52 to 91)
Serotype 11A2966 (2212 to 3978)66 (51 to 85)
Serotype 12F5501 (4499 to 6725)29 (25 to 35)
Serotype 15B2676 (1948 to 3677)23 (18 to 30)
Serotype 22F6523 (4848 to 8777)17 (13 to 24)
Serotype 33F11315 (8107 to 15794)708 (545 to 920)
SecondaryGeometric Mean Fold Rise (GMFRs) of IgG Concentrations From Before Dose 3 to 1 Month After Dose 3: Primary Study Population

20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution).

Time frame:
Before Dose 3 to 1 month after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFRs) of IgG Concentrations From Before Dose 3 to 1 Month After Dose 3: Primary Study Population
Fold rise20vPnC: Primary Study Population13vPnC: Primary Study Population
Serotype 113.9 (12.7 to 15.3)13.9 (12.8 to 15.1)
Serotype 313.7 (12.4 to 15.1)15.2 (13.9 to 16.7)
Serotype 429.8 (27.0 to 32.9)27.7 (25.0 to 30.6)
Serotype 514.0 (12.9 to 15.2)13.6 (12.6 to 14.7)
Serotype 6A26.9 (24.2 to 30.0)28.7 (25.9 to 31.7)
Serotype 6B36.8 (33.3 to 40.6)40.2 (36.8 to 44.0)
Serotype 7F8.5 (7.9 to 9.2)9.3 (8.6 to 10.0)
Serotype 9V22.5 (20.4 to 24.7)19.9 (18.3 to 21.6)
Serotype 149.7 (8.7 to 10.8)8.4 (7.6 to 9.4)
Serotype 18C15.8 (14.5 to 17.1)17.0 (15.7 to 18.4)
Serotype 19A39.3 (34.6 to 44.7)40.7 (36.4 to 45.5)
Serotype 19F20.5 (18.4 to 22.9)21.4 (19.4 to 23.7)
Serotype 23F32.3 (29.2 to 35.7)38.3 (34.7 to 42.4)
Serotype 812.7 (11.6 to 13.9)1.4 (1.3 to 1.5)
Serotype 10A14.8 (13.3 to 16.4)1.1 (1.0 to 1.2)
Serotype 11A13.8 (12.4 to 15.3)1.1 (1.0 to 1.2)
Serotype 12F16.5 (15.0 to 18.0)1.0 (1.0 to 1.1)
Serotype 15B13.4 (11.9 to 15.1)1.3 (1.2 to 1.4)
Serotype 22F12.8 (11.5 to 14.3)1.3 (1.1 to 1.4)
Serotype 33F12.9 (11.6 to 14.3)1.1 (1.0 to 1.2)
SecondaryPercentage of Participants With Predefined Antibody Levels for Concomitant Vaccine Antigens 1 Month After Dose 2: Primary Study Population

Pre-specified vaccines were administered concomitantly with 20vPnC or 13vPnC and responses assessed using pre-defined levels as follows: Diphtheria and tetanus toxoids: concentration of antibody (in international units \[IU\]) to diphtheria and tetanus toxoid (prespecified level \>= observed anti-pertussis antibody concentration achieved by 95% of 13vPnC recipients); Poliomyelitis: NA titers to poliovirus types 1, 2, and 3 (prespecified level NA titer \>=1:8); and Hib: concentration of antibody to Hib (PRP) in mcg/mL (prespecified level \>=0.15 mcg/mL anti-PRP). 2-sided 95% CI was based on Clopper and Pearson method. The assays were performed on randomly selected subsets.

Time frame:
1 month after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Antibody Levels for Concomitant Vaccine Antigens 1 Month After Dose 2: Primary Study Population
Percentage of participants20vPnC: Primary Study Population13vPnC: Primary Study Population
Diphtheria toxoid85.0 (79.3 to 89.6)89.5 (84.4 to 93.4)
Tetanus toxoid95.5 (91.6 to 97.9)98.5 (95.7 to 99.7)
Pertussis: PT94.5 (90.4 to 97.2)95.0 (91.0 to 97.6)
Pertussis: FHA93.5 (89.1 to 96.5)95.0 (91.0 to 97.6)
Pertussis: PRN93.5 (89.1 to 96.5)95.0 (91.0 to 97.6)
Poliovirus: Type 194.8 (88.3 to 98.3)98.1 (93.2 to 99.8)
Poliovirus: Type 288.5 (80.4 to 94.1)91.3 (84.2 to 96.0)
Poliovirus: Type 395.8 (89.7 to 98.9)100.0 (96.5 to 100.0)
Hemophilus influenzae type b100.0 (98.2 to 100.0)100.0 (98.1 to 100.0)
Statistical analysis
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -4.5 · 95% CI -11.2 to 2.12-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -3.0 · 95% CI -7.0 to 0.42-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -0.5 · 95% CI -5.2 to 4.12-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -1.5 · 95% CI -6.4 to 3.32-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -1.5 · 95% CI -6.4 to 3.32-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -3.3 · 95% CI -10.0 to 2.22-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -2.8 · 95% CI -11.8 to 5.82-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: -4.2 · 95% CI -10.2 to -0.52-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
  • 20vPnC: Primary Study Population vs 13vPnC: Primary Study Population · Percent difference: 0.0 · 95% CI -1.8 to 2.02-Sided 95% CI based on the Miettinen and Nurminen method for the difference in proportions (20vPnC - 13vPnC) expressed as a percentage.
SecondaryPercentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 3: Russian Cohort

Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

Time frame:
1 Month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 3: Russian Cohort
Percentage of participants20vPnC: Russian Cohort13vPnC: Russian Cohort
Serotype 190.9 (70.8 to 98.9)83.3 (62.6 to 95.3)
Serotype 368.2 (45.1 to 86.1)50.0 (29.1 to 70.9)
Serotype 495.5 (77.2 to 99.9)100.0 (85.8 to 100.0)
Serotype 590.9 (70.8 to 98.9)91.7 (73.0 to 99.0)
Serotype 6A95.5 (77.2 to 99.9)100.0 (85.8 to 100.0)
Serotype 6B90.9 (70.8 to 98.9)91.7 (73.0 to 99.0)
Serotype 7F95.5 (77.2 to 99.9)100.0 (85.8 to 100.0)
Serotype 9V100.0 (84.6 to 100.0)83.3 (62.6 to 95.3)
Serotype 1490.9 (70.8 to 98.9)100.0 (85.8 to 100.0)
Serotype 18C90.9 (70.8 to 98.9)95.8 (78.9 to 99.9)
Serotype 19A100.0 (84.6 to 100.0)95.8 (78.9 to 99.9)
Serotype 19F100.0 (84.6 to 100.0)91.7 (73.0 to 99.0)
Serotype 23F90.9 (70.8 to 98.9)79.2 (57.8 to 92.9)
Serotype 868.2 (45.1 to 86.1)25.0 (9.8 to 46.7)
Serotype 10A68.2 (45.1 to 86.1)16.7 (4.7 to 37.4)
Serotype 11A77.3 (54.6 to 92.2)20.8 (7.1 to 42.2)
Serotype 12F36.4 (17.2 to 59.3)4.2 (0.1 to 21.1)
Serotype 15B90.9 (70.8 to 98.9)20.8 (7.1 to 42.2)
Serotype 22F63.6 (40.7 to 82.8)12.5 (2.7 to 32.4)
Serotype 33F72.7 (49.8 to 89.3)20.8 (7.1 to 42.2)
SecondaryGMTs of Serotype-specific OPA at 1 Month After Dose 2: Russian Cohort

OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 2. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the student's t distribution.

Time frame:
1 month after Dose 2
Reported as:
Geometric mean · Titers
GMTs of Serotype-specific OPA at 1 Month After Dose 2: Russian Cohort
Titers20vPnC: Russian Cohort13vPnC: Russian Cohort
Serotype 117 (7 to 40)33 (10 to 105)
Serotype 379 (42 to 149)31 (13 to 73)
Serotype 4166 (38 to 736)163 (32 to 840)
Serotype 528 (11 to 76)31 (14 to 71)
Serotype 6A222 (32 to 1553)247 (60 to 1011)
Serotype 6B314 (27 to 3584)216 (39 to 1186)
Serotype 7F809 (481 to 1361)717 (246 to 2084)
Serotype 9V218 (70 to 676)293 (85 to 1008)
Serotype 14984 (492 to 1970)247 (69 to 886)
Serotype 18C968 (403 to 2326)268 (43 to 1655)
Serotype 19A314 (68 to 1443)31 (8 to 118)
Serotype 19F120 (27 to 529)230 (48 to 1097)
Serotype 23F35 (6 to 196)56 (9 to 346)
Serotype 8203 (19 to 2155)38 (9 to 161)
Serotype 10A559 (50 to 6233)232 (8 to 6478)
Serotype 11A3537 (863 to 14497)2717 (470 to 15716)
Serotype 12F698 (77 to 6301)198 (41 to 960)
Serotype 15B142 (9 to 2269)242 (18 to 3267)
Serotype 22F413 (32 to 5406)499 (28 to 8837)
Serotype 33F3508 (349 to 35250)3961 (706 to 22238)
SecondaryGMTs of Serotype-specific OPA at 1 Month After Dose 3: Russian Cohort

OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the student's t distribution.

Time frame:
1 Month after Dose 3
Reported as:
Geometric mean · Titers
GMTs of Serotype-specific OPA at 1 Month After Dose 3: Russian Cohort
Titers20vPnC: Russian Cohort13vPnC: Russian Cohort
Serotype 185 (17 to 421)93 (22 to 394)
Serotype 3126 (41 to 383)107 (37 to 309)
Serotype 4310 (86 to 1123)429 (38 to 4863)
Serotype 5116 (28 to 476)108 (26 to 456)
Serotype 6A2922 (311 to 27459)1580 (393 to 6351)
Serotype 6B4417 (998 to 19951)1397 (150 to 12967)
Serotype 7F1039 (509 to 2122)1411 (373 to 5340)
Serotype 9V1574 (369 to 6711)1067 (150 to 7583)
Serotype 141151 (321 to 4132)628 (137 to 2890)
Serotype 18C583 (149 to 2284)973 (89 to 10606)
Serotype 19A652 (131 to 3234)435 (14 to 13833)
Serotype 19F1570 (239 to 10337)701 (124 to 3958)
Serotype 23F152 (24 to 966)410 (22 to 7594)
Serotype 8368 (11 to 12078)149 (9 to 2337)
Serotype 10A2851 (1309 to 6210)117 (15 to 916)
Serotype 11A7137 (1036 to 49164)1789 (36 to 89068)
Serotype 12F757 (15 to 37522)241 (16 to 3734)
Serotype 15B822 (42 to 16070)147 (10 to 2214)
Serotype 22F1983 (390 to 10085)1635 (165 to 16157)
Serotype 33F5903 (53 to 657862)3619 (948 to 13817)

Adverse events

Collected over Local reactions and Systemic events (systematic assessment): Within 7 days after Dose 1, 2, or 3; SAEs (non-systematic assessment): From Dose 1 up to 1 month after Dose 3 and other AEs (non-systematic assessment): From Dose 1 up to 1 month after Dose 2 and from Dose 3 up to 1 month after Dose 3. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20vPnC: Primary Study Population0/601 (0%)34/601 (5.7%)589/601 (98%)
13vPnC: Primary Study Population0/603 (0%)40/603 (6.6%)593/603 (98.3%)
20vPnC: Russian Cohort0/24 (0%)0/24 (0%)17/24 (70.8%)
13vPnC: Russian Cohort0/27 (0%)0/27 (0%)20/27 (74.1%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
Event20vPnC: Primary Study Population13vPnC: Primary Study Population20vPnC: Russian Cohort13vPnC: Russian Cohort
GastroenteritisInfections and infestations4/6015/6030/240/27
Urinary tract infectionInfections and infestations4/6014/6030/240/27
Viral infectionInfections and infestations3/6011/6030/240/27
PneumoniaInfections and infestations1/6013/6030/240/27
Feeding disorderMetabolism and nutrition disorders0/6013/6030/240/27
BronchiolitisInfections and infestations2/6012/6030/240/27
Gastrointestinal infectionInfections and infestations2/6012/6030/240/27
Respiratory syncytial virus bronchiolitisInfections and infestations2/6011/6030/240/27
Escherichia urinary tract infectionInfections and infestations0/6012/6030/240/27
LaryngitisInfections and infestations1/6012/6030/240/27
Most frequent other events
Most frequent other events
Event20vPnC: Primary Study Population13vPnC: Primary Study Population20vPnC: Russian Cohort13vPnC: Russian Cohort
Irritability (IRRITABILITY)Psychiatric disorders553/601556/60313/2415/27
Hypersomnia (INCREASED SLEEP)Nervous system disorders495/601512/6038/2411/27
Injection site pain (PAIN)General disorders343/601347/6037/246/27
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders345/601323/6039/248/27
Injection site erythema (REDNESS)General disorders331/601333/6033/244/27
Injection site swelling (SWELLING)General disorders260/601251/6034/243/27
Pyrexia (FEVER)General disorders212/601214/6032/244/27
Upper respiratory tract infectionInfections and infestations21/60135/6031/240/27

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of 20vPnC or 13vPnC and had safety data assessed after any dose.

Age, Customized
Age, Customized(Participants)20vPnC: Primary Study Population13vPnC: Primary Study Population20vPnC: Russian Cohort13vPnC: Russian CohortTotal
28 days-23 months60160324271255
Sex: Female, Male
Sex: Female, Male(Participants)20vPnC: Primary Study Population13vPnC: Primary Study Population20vPnC: Russian Cohort13vPnC: Russian CohortTotal
Female3022921612622
Male299311815633
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20vPnC: Primary Study Population13vPnC: Primary Study Population20vPnC: Russian Cohort13vPnC: Russian CohortTotal
Hispanic or Latino41005
Not Hispanic or Latino57758622251210
Unknown or Not Reported20162240
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20vPnC: Primary Study Population13vPnC: Primary Study Population20vPnC: Russian Cohort13vPnC: Russian CohortTotal
American Indian or Alaska Native00000
Asian850114
Native Hawaiian or Other Pacific Islander00000
Black or African American01001
White58559224261227
More than one race10001
Unknown or Not Reported750012
08

Study locations

66 sites
  • Perth Children's Hospital
    Nedlands, Western Australia 6009, Australia
  • Telethon Kids Institute, Vaccine Trials Group, Perth Children's Hospital
    Nedlands, Western Australia 6009, Australia
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • University Hospital Antwerp
    Edegem, 2650, Belgium
  • DD ordinace s.r.o.
    Jindrichuv Hradec, 377 01, Czechia
  • Ordinace praktického lékaře pro děti a dorost
    Jindrichuv Hradec, 377 01, Czechia
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Jindrichuv Hradec, 377 01, Czechia
  • Zdravotnicke stredisko Dubina, verejna obchodni spolecnost
    Pardubice, 530 12, Czechia
  • MUDr. Jitka Fabianova
    Praha 3, 130 00, Czechia
  • MEDICENTRUM 6 s.r.o. - Ordinace praktickeho lekare pro deti a dorost
    Praha 6, 160 00, Czechia
  • Medicentrum 6 s.r.o.
    Praha 6, 160 00, Czechia
  • Hvidovre Hospital
    Hvidovre, 2650, Denmark
  • Kadrina Tervisekeskus OU
    Kadrina, 45201, Estonia
  • Merekivi Perearstid.
    Tallinn, 10617, Estonia
  • Merelahe Family Doctors Centre
    Tallinn, 10617, Estonia
  • OU Al Mare Perearstikeskus
    Tallinn, 10617, Estonia
  • Sinu Arst Health Center
    Tallinn, 11313, Estonia
  • Clinical Research Centre
    Tartu, 50106, Estonia
  • Espoo Vaccine Research Clinic
    Espoo, 02230, Finland
  • Helsinki South Vaccine Research Clinic
    Helsinki, 00100, Finland
  • Helsinki East Vaccine Research Clinic
    Helsinki, 00930, Finland
  • Jarvenpaa Vaccine Research Clinic
    Jarvenpaa, 04400, Finland
  • Kokkola Vaccine Research Clinic
    Kokkola, 67100, Finland
  • FVR, Oulun rokotetutkimusklinikka
    Oulu, 90220, Finland
  • Tampereen yliopisto Oulun Rokotetutkimusklinikka
    Oulu, 90220, Finland
  • Pori Vaccine Research Clinic
    Pori, 28100, Finland
  • Seinäjoki Vaccine Research Clinic
    Seinajoki, 60100, Finland
  • Tampere Vaccine Research Center
    Tampere, 33100, Finland
  • Turku Vaccine Research Clinic
    Turku, 20520, Finland
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico U.O.S.D. Pediatria Alta lntensita di Cura
    Milano, Milan 20122, Italy
  • Azienda Ospedaliero Universitaria Meyer
    Firenze, 50139, Italy
  • Azienda Ospedaliera Universitaria
    Foggia, 71122, Italy
  • Ospedale Policlinico San Martino
    Genova, 16132, Italy
  • Stichting Apotheek der Haarlemse Ziekenhuizen
    Haarlem, 2035 RC, Netherlands
  • Spaarne Gasthuis (Kennemer Gasthuis)
    Hoofddorp, 2134 TM, Netherlands
  • Akershus University Hospital
    Lorenskog, 1478, Norway
  • Oslo University Hospital, Ulleval
    Oslo, 0450, Norway
  • Stavanger University Hospital
    Stavanger, 4011, Norway
  • Akershus University Hospital - Sykehusapoteket Ahus
    Viken, 1474, Norway
  • IN-VIVO Sp z o.o. IN-VIVO Bydgoszcz
    Bydgoszcz, 85-048, Poland
  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Prywatny Gabinet Lekarski dr n. med. Jerzy Brzostek
    Debica, 39-200, Poland
  • Centrum Badan Klinicznych JCI
    Krakow, 30-348, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawla II Oddzial Pediatrii i Neurologii Dzieciecej
    Krakow, 31-202, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "SALMED"
    Leczna, 21-010, Poland
  • GRAVITA. Diagnostyka i Leczenie nieplodnosci
    Lodz, 91-347, Poland
  • Rodzinne Centrum Medyczne LUBMED
    Lubon, 62-030, Poland
  • Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem w Poznaniu
    Poznan, 60-663, Poland
  • Niepubliczny Zaklad Lecznictwa Ambulatoryjnego Michalkowice Jarosz i Partnerzy Spolka Lekarska
    Siemianowice Slaskie, 41-103, Poland
  • Nasz Lekarz Przychodnie Medyczne Slawomir Jeka
    Torun, 87-100, Poland
  • Szpital im. Sw. Jadwigi Slaskiej w Trzebnicy
    Trzebnica, 55-100, Poland
  • Szpital Bielanski im. ks. J. Popieluszki SPZOZ
    Warszawa, 01-809, Poland
  • Provita 001
    Warszawa, 02-647, Poland
  • Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu
    Wroclaw, 50-368, Poland
  • Centrum Medyczne AD-MED Sp. z o. o. Przychodnia Dla Rodziny
    Wroclaw, 51-141, Poland
  • State autonomous institution of healthcare of Sverdlovsk region
    Ekaterinburg, 620028, Russian Federation
  • Federal State Budget Institution of Healthcare Central clinical hospital of Russian
    Moscow, 119333, Russian Federation
  • State Budget Institution of Healthcare of Perm Region "City Children's Clinical Polyclinic #5"
    Perm, 614066, Russian Federation
  • LLC PiterClinica
    Saint Petersburg, 196158, Russian Federation
  • PEDIAMED s.r.o.
    Bratislava, 831 03, Slovakia
  • NASA DOKTORKA s.r.o.
    Bratislava, 841 02, Slovakia
  • Rozvojova agentura Banskobystrickeho samospravneho kraja, n.o.
    Detva, 962 12, Slovakia
  • MUDr. Martin Zavrel Vseobecna ambulancia pre deti a dorast
    Horne Srnie, 91442, Slovakia
  • Všeobecná ambulancia pre deti a dorast
    Humenne, 06601, Slovakia
  • PEDAMB s.r.o.
    Kosice, 040 11, Slovakia
  • MUDr. Drusková s.r.o.
    Liptovská Osada, 034 73, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Apr 2022, 19 months.

Results were first posted in May 2023, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 19 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2020
First posted
Sep 14, 2020
StartActual
Sep 9, 2020
Primary completionActual
Apr 22, 2022
CompletionActual
Feb 18, 2023
Results first posted
May 15, 2023
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04546425
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Sep 9, 2020
Primary completion
Apr 22, 2022
Completion
Feb 18, 2023
Results posted
May 15, 2023
Last update
Jan 8, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion